<DOC>
	<DOCNO>NCT00631150</DOCNO>
	<brief_summary>Patients community-based practice correspond 25 % patient need first add-on drug control standard monotherapy drug . This therapeutic use trial population correspond closely see daily clinical practice .</brief_summary>
	<brief_title>A Phase IV-Pharmacovigilance Study Keppra Greece - S.K.A.T.E . : Safety Keppra Adjunctive Therapy Epilepsy</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<criteria>partial onset seizure without secondary generalisation epilepsy . hypersensitivity levetiracetam pyrrolidone derivative excipients .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Levetiracetam</keyword>
	<keyword>Keppra</keyword>
</DOC>